FDA COVID vaccine update is stirring major public attention as a new policy limits fall COVID-19 booster shots to seniors and ...

Advisers to the FDA will debate if the virus has mutated enough since last winter to require a tweak to the formula.

The FDA has approved Nuvaxovid to prevent COVID-19 in adults 65 years and older and high-risk individuals 12 through 64 years ...

Novavax's full FDA approval for NUVAXOVID is a transformative milestone, unlocking a $175M Sanofi payment and validating ...

Novavax can finally breathe a sigh of relief – at least a small one. The Food and Drug Administration approved the company's ...

The FDA has approved the Novavax COVID-19 vaccine, called Nuvaxovid, mainly for adults 65 or older, but people ages 12 to 64 with medical conditions that increase their risk of serious illness from ...

Novavax makes the nation’s only traditional protein-based coronavirus vaccine – and until now it had emergency authorization ...

May 8, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the first quarter ended March 31, 2025. "I am pleased with the ...

View original content to download multimedia:https://www.prnewswire.com/news-releases/novavax-reports-first-quarter-2025-financial-results-and-operational-highlights ...

GAITHERSBURG, Md. (AP) — GAITHERSBURG, Md. (AP) — Novavax Inc. (NVAX) on Thursday reported first-quarter profit of $518.6 million. On a per-share basis, the Gaithersburg, Maryland-based ...

GAITHERSBURG, Md., April 29, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced the appointment of Charles Newton to its board as an independent director. Mr. Newton brings extensive ...

WASHINGTON (AP) — The Trump administration’s effort to impose new requirements on Novavax’s COVID-19 vaccine — the nation’s only traditional protein-based option for the coronavirus ...